Use of Biomarkers in Prognosis and treatment of Cancer

Gayatri Varikuti
Department Of Biochemistry, GITAM Institute Of Science, GITAM University, Visakhapatnam, India

Published on: 2020-12-29

Abstract

Now a days the goal of the treatment for cancer relays on the biomarker/tumor-associated antigens. Radiolabelled MoAbs, monoclonal antibodies, antibody-drug conjugates, and bispecific T cell engagers include antibody form compounds targeting cancer biomarkers. The analysis of a patient sample for cancers that affect the blood, bone marrow, and lymph nodes tumors include antibodies intended SLAMF7, CD19, 20, 22, 30, 33, 38, and CD79B. The aim for cancer immunotherapeutic representatives, like B cell maturation antigen, chimeric antigen receptor engineered T cells, CLL-1, CD138 and CD123. PD-1, PD-L1, and CTLA-4 immune checkpoint inhibitors have contributed to the cancer treatment innovations. Inhibitors are being investigated in the immune control point targeting LAG3, IDO, SIGLECs, CD47TIM-3, TIGIT, and VISTA. The scene of cancer therapy has been radically altered with the small molecular regulators of tyrosin kinases oncoproteins like ALK, Bruton tyrosin kinase, FGFR, JAK2, MEK, MET, BCR-ABL, HER2, EGFR, FLT3, and VEGFR. The cure of various forms of cancer has been primarily sponsored by SMIs for BRAF, BCL-2, CDKs, IDHs, mTOR, PI3 kinoasis, and PARP [1-4]. Cancer-specific TAAs like CD33 was developed for strategy that can prevent or reduce toxicity from off-tumor. The future developments in cancer Therapies is accelerating the hunt for latest biomarkers or current pattern and distribution towards selective targets [5-9].

Keywords

Biomarkers, Cancer and Therapy, Chemotherapeutic Drugs

Introduction

Now a days the goal of the treatment for cancer relays on the biomarker/tumor-associated antigens. Radiolabelled MoAbs, monoclonal antibodies, antibody-drug conjugates, and bispecific T cell engagers include antibody form compounds targeting cancer biomarkers.The analysis of a patient sample for cancers that affect the blood, bone marrow, and lymph nodes tumors include antibodies intended SLAMF7, CD19,20,22,30,33,38, and CD79B. The aim for cancer immunotherapeutic representatives, like B cell maturation antigen, chimeric antigen receptor engineered T cells, CLL-1, CD138 and CD123. PD-1, PD-L1, and CTLA-4 immune checkpoint inhibitors have contributed to the cancer treatment innovations. Inhibitors are being investigated in the immune control point targeting LAG3, IDO, SIGLECs, CD47TIM-3, TIGIT, and VISTA. The scene of cancer therapy has been radically altered with the small molecular regulators of tyrosin kinases oncoproteins like ALK, Bruton tyrosin kinase, FGFR, JAK2, MEK, MET, BCR-ABL, HER2, EGFR, FLT3, and VEGFR. The cure of various forms of cancer has been primarily sponsored by SMIs for BRAF, BCL-2, CDKs, IDHs, mTOR, PI3 kinoasis, and PARP [1-4]. Cancer-specific TAAs like CD33 was developed for strategy that can prevent or reduce toxicity from off-tumor. The future developments in cancer Therapies is accelerating the hunt for latest biomarkers or current pattern and distribution towards selective targets [5-9].

The biomarker of cancer treatment was CD19 with much more emphasis. Besides research uses, CAR-T and blinatumomab drugs authorized for future administration. Further CD19, including loncastuximab tesirine, denintuzumab mafodtoin and coltuximab ravtansine are available in research studies. That was valuable that aimed to CD19 CAR-T and Tisgenlecleucel, showed efficacy for high-dose Alkeran and transplation of origin stem cell to treat cancers [10-13].

Besides lymphoid malignancies, MoAbs targeting CD20 were wornextensively. The utilization of ADCs for chemo-immunotherapy is rising very high. To diagnosis of lymphoid malignancies, 4 latest ADCs were already implemented: inotuzumab ozogamicin, brentuximab vedotin targeting CD30, polatuzumab vedotin targeting CD79b and moxetumomab pasudotox targeting CD22. Further biomarkers including ADCs/CAR-T cells indeed being investigated like CD25,37,56,70,74, and CD138 are such biomarkers [14-19].

Gemtuzumab would be a CD33-dependent ADC frequently exhibited in myeloid cells. To treat refractory acute myeloid leukemia, and GO has been accepted. The single agent/conjunction with chemotherapeutic drugs, GO can be used.Furthermore, multiple innovative CD33-targeted ADCs are still ongoing advance drug discovery like AVE9633, IMGN779, and Talirine vadastuximab [20-26].

Recent medical studies, ADCs that approach CD123, along with SGN-CD123A and IMGN632 are under investigation. However, health and safety issues, future production on SGN-123A has been suspended [27].

Typically, clinical development or initial clinical trials for AML were ongoing for BiTE including ADCs targeting CLL-1. During clinical studies for AML therapy, CLL 1 directed CAR-T cells are present [28].

CTLA-4, PD-L1 and PD-1 immune checkpoint modifiers have contributed to a profound paradigm change in preclinical studies. The unique distinction of traditional chemotherapy ICIs seems to be that rather than just cancer cells, the ICIs strike immune cells and seek to attenuate the micro - environment of the cancer, contributing to the enhancement of depleted cancer resistance. Other immune inspection biomarkers, particularly CD47, TIGIT LAG3, IDO, SIGLECs, TIM-3 and VISTA being driving focused entity production [29-32].

The solid tumors, particularly CD133-targeted CAR T cells, cholangiocarcinoma were utilized. For gastric, breast, lung, pancreatic cancers and mesothelioma, Mesothelin controlled CAR-T cells were already registered. Claudin 18.2, GFR and HER2 are the selected strategies, particularly MoAbs and CAR-T for tumor immunotherapy [33-37].

A modern concept of engineered cancer targeted biomarkers for cancer treatment unlocked the strategy through device science as well as technology. The quest for potential therapeutics and experimental research, and also distribution systems like selective vector nano-technology are accelerating the future for cancer treatment.

References

  1. Owen CJ, Stewart DA (2015) Obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia: overview and perspective. Ther Adv Hematol 4: 161-70.https://doi.org/10.1177/2040620715586528
  2. Shah A (2014) Obinutuzumab: a novel anti-CD20 monoclonal antibody for previously untreated chronic lymphocytic leukemia. Ann Pharmacother 48: 1356-61.https://doi.org/10.1177/1060028014543271
  3. Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, et al. (2014) Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 370: 1101-10.https://doi.org/10.1056/NEJMoa1313984
  4. Shah A (2015) New developments in the treatment of chronic lymphocytic leukemia: role of obinutuzumab. Ther Clin Risk Manag 11: 1113-1122.https://doi.org/10.2147/TCRM.S71839
  5. Kantarjian H, Stein A, Gokbuget N, Fielding AK, Schuh AC, et al. (2017) Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 376: 836-47.
  6. Porter DL, Levine BL, Kalos M, Bagg A, June CH (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365: 725-33.https://doi.org/10.1056/NEJMoa1103849
  7. Miliotou AN, Papadopoulou LC (2018) CAR T-cell therapy: a new era in cancer immunotherapy. Curr Pharm Biotechnol 19: 5-18.https://doi.org/10.2174/1389201019666180418095526
  8. Salter AI, Pont MJ, Riddell SR (2018) Chimeric antigen receptor–modified T cells: CD19 and the road beyond. Blood 131: 2621-9.https://doi.org/10.1182/blood-2018-01-785840
  9. Santasusana JM, de Andrés Saldaña A, García-Muñoz N, Gostkorzewicz J, Llinàs DM, et al. (2020) Cost-Effectiveness Analysis of Tisagenlecleucel in the Treatment of Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia in Children and Young Adults in Spain. Clinicoeconomics and Outcomes Research: CEOR 12: 253-264.https://doi.org/10.2147/CEOR.S241880
  10. Jackson HJ, Rafiq S, Brentjens RJ (2016) Driving CAR T-cells forward. Nat Rev Clin Oncol 13: 370-383.https://doi.org/10.1038/nrclinonc.2016.36
  11. Nair R, Neelapu SS (2018) The promise of CAR T-cell therapy in aggressive B-cell lymphoma. Best Pract Res Clin Haematol 31: 293-8.https://doi.org/10.1016/j.beha.2018.07.011
  12. Garfall AL, Stadtmauer EA, Hwang WT, Lacey SF, Melenhorst JJ, et al. (2018) Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight 3: 1-14.https://doi.org/10.1172/jci.insight.120505
  13. Li D, Hu Y, Jin Z, Zhai Y, Tan Y, et al. (2018) TanCAR T cells targeting CD19 and CD133 efficiently eliminate MLL leukemic cells. Leukemia 32: 2012-6.https://doi.org/10.1038/s41375-018-0212-z
  14. Ribrag V, Koscielny S, Bosq J, Leguay T, Casasnovas O, et al. (2016) Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial. Lancet 387: 2402-11.https://doi.org/10.1016/S0140-6736(15)01317-3
  15. Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, et al. (2012) Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol 30: 1822.https://doi.org/10.1200/JCO.2011.38.1756
  16. Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, et al. (2020) Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 38: 155-65.https://doi.org/10.1200/JCO.19.00172
  17. Janus A, Robak T (2019) Moxetumomab pasudotox for the treatment of hairy cell leukemia. Exp Opinion Biol Ther 19: 501-8.https://doi.org/10.1080/14712598.2019.1614558
  18. Foyil KV, Bartlett NL (2011) Brentuximab vedotin for the treatment of CD30+ lymphomas. Immunother 3: 475-85.https://doi.org/10.2217/imt.11.15
  19. Wolska-Washer A, Robak P, Smolewski P, Robak T (2017) Emerging antibody-drug conjugates for treating lymphoid malignancies. Exp Opinion Emerg Drugs 22: 259-73.https://doi.org/10.1080/14728214.2017.1366447
  20. Ravandi F, Kantarjian H (2012) Gemtuzumab ozogamicin in acute myeloid leukaemia. Nat Rev Clin Oncol 9: 310-1.https://doi.org/10.1038/nrclinonc.2012.83
  21. Rowe JM, Löwenberg B (2013) Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug. Blood 121: 4838-41.https://doi.org/10.1182/blood-2013-03-490482
  22. Amadori S, Suciu S, Selleslag D, Stasi R, Alimena G, et al. (2010) Randomized trial of two schedules of low?dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML?19). Bri J Haematol 149: 376-82.https://doi.org/10.1111/j.1365-2141.2010.08095.x
  23. Whiteman KR, Noordhuis P, Walker R, Watkins K, et al. (2014) The antibody-drug conjugate (ADC) IMGN779 is highly active in vitro and in vivo against acute myeloid leukemia (AML) with FLT3-ITD mutations. Blood 124: 2321.https://doi.org/10.1182/blood.V124.21.2321.2321
  24. Kung Sutherland MS, Walter RB, Jeffrey SC, Burke PJ, Yu C, et al. (2013) SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood 122: 1455-63.https://doi.org/10.1182/blood-2013-03-491506
  25. Giles F, Morariu-Zamfir R, Lambert J, Verstovsek S, Thomas D, et al. (2006) Phase I Study of AVE9633, an AntiCD33-Maytansinoid Immunoconjugate, Administered as an Intravenous Infusion in Patients with Refractory/Relapsed CD33-Positive Acute Myeloid Leukemia (AML). Blood 108: 4548.https://doi.org/10.1182/blood.V108.11.4548.4548
  26. Lichtenegger FS, Krupka C, Haubner S, Köhnke T, Subklewe M (2017) Recent developments in immunotherapy of acute myeloid leukemia. J Hematol Oncol 10: 142.https://doi.org/10.1186/s13045-017-0505-0
  27. Li F, Sutherland MK, Yu C, Walter RB, Westendorf L, et al. (2018) Characterization of SGN-CD123A, a potent CD123-directed antibody–drug conjugate for acute myeloid leukemia. Mol Cancer Therap17: 554-64.https://doi.org/10.1158/1535-7163.MCT-17-0742
  28. Ma H, Padmanabhan IS, Parmar S, Gong Y (2019) Targeting CLL-1 for acute myeloid leukemia therapy. J Hematol Oncol 12: 41.https://doi.org/10.1186/s13045-019-0726-5
  29. Diggs LP, Hsueh EC (2017) Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response. Biomarker Res 5: 12.https://doi.org/10.1186/s40364-017-0093-8
  30. Motzer RJ, Robbins PB, Powles T, Albiges L, Haanen JB, et al. (2020) Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. Nat Med 26: 1733-41.https://doi.org/10.1038/s41591-020-1044-8
  31. Wang J, Sun J, Liu LN, Flies DB, Nie X, et al. (2019) Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. Nat Med 25: 656-66.https://doi.org/10.1038/s41591-019-0374-x
  32. Liu D (2019) Cancer biomarkers for targeted therapy. Biomarker Res 7: 25.https://doi.org/10.1186/s40364-019-0178-7
  33. Mehrazma M, Madjd Z, Kalantari E, Panahi M, Hendi A, et al. (2013) Expression of stem cell markers, CD133 and CD44, in pediatric solid tumors: a study using tissue microarray. Fetal Pediat Pathol 32: 192-204.https://doi.org/10.3109/15513815.2012.701266
  34. Hassan R, Ho M (2008) Mesothelin targeted cancer immunotherapy. Eur J Cancer 44: 46-53.https://doi.org/10.1016/j.ejca.2007.08.028
  35. Zhang E, Gu J, Xu H (2018) Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors. Mol Cancer 17: 7.https://doi.org/10.1186/s12943-018-0759-3
  36. Ecsedi M, McAfee MS, Chapuis AG (2020) The Anticancer Potential of T Cell Receptor-Engineered T Cells. Trend Cancer 7: 48-56.https://doi.org/10.1016/j.trecan.2020.09.002
  37. Evdokimova VN, Liu Y, Potter DM, Butterfield LH (2007) AFP-specific CD4+ helper T-cell responses in healthy donors and HCC patients. J Immunother 30: 425-37.https://doi.org/10.1097/CJI.0b013e31802fd8e2
scroll up